Examplepictures of DNA-Structures
Monday Tuesday Wednesday Thursday Friday Saturday Sunday

Page 1 of 1 1

April 01 - April 30

5 entries found

Smart mater..
Start date: April 02
05:00 pm 06:00 pm

Gene regula..
Start date: April 05
04:00 pm 05:00 pm


Speaker: Dr. Mareike Albert

Title: Gene regulatory mechanisms of neocortex development and evolution

Epigenetic mechanisms play a pivotal role in orchestrating the behavior of stem cells during development. We are interested in the mechanisms that regulate gene expression in neural stem and progenitor cells, which have implications for our understanding of neocortex development and evolution as well as neural stem cell regulation.


Speaker: Dr. Seba Almedawar

Title: CLEANSIGHT: from basic human RPE cell biology to disease modeling and therapy discovery

Inherited and age acquired retinal degenerative diseases (RD) are the primary cause of vision loss in the industrialized world. The retinal pigment epithelium (RPE) is implicated in many RD, including age related macular degeneration (AMD), Best1 disease and retinitis pigmentosa. A decade ago, studying those diseases in vitro was challenging due to limited access to patient RPE, which hampered the development of therapy. In CLEANSIGHT, we use human pluripotent stem cells derived RPE to study and model RD and develop therapeutic approaches using small molecules or cell replacement therapy. Our established screening platform revealed stimulators of photoreceptor outer segment phagocytosis, which is a major disease causing phenotype in RD. Currently we are validating our favorite hit in vivo and transferring our finding to industry for drug development. In parallel, we have made the first steps to transfer our protocol to more defined and animal origin free media, which is required for cell replacement therapy. Additionally, in collaboration with Prof. Marius Ader and Miltenyi Biotec, we have identified cell surface markers that can be used to purify RPE cells from remnant stem cells before transplantation, which is a challenge in the field. By establishing both small molecules and cell replacement therapy approaches, the best treatment strategy can be chosen based on the RD stage (early vs late), on a patient-to-patient basis.

Start date: April 11
11:00 am 12:00 pm



Speaker: Prof. Dr. Frank Buchholz, TU Dresden, Faculty of Medicine, University Cancer Center

Title: "Programmable nucleases and designer recombinases for genome surgery"

Abstract: Recent breakthroughs in the field of genome editing provide a genuine opportunity to establish innovative gene and cell therapy approaches to repair DNA lesions to replace, engineer or regenerate malfunctioning cells in vitro, or directly in the human body. Most of the recently developed genome editing technologies introduce double stranded DNA breaks at a target locus. These breaks are subsequently repaired by one of the cell intrinsic DNA repair mechanisms, typically inducing an abundance of random insertions and deletions (indels) at the target locus. We have employed the CRISPR/Cas9 system to utilize this property to investigate cancer mutations. How this approach can be used to dissect driver mutations from passenger mutations and how this knowledge could help to improve personalized therapies will be discussed.

For other applications, therapeutic genome editing should, however, be efficient and specific, without the introduction of indels. Site-specific recombinases (SSRs) allow genome editing without triggering cell intrinsic DNA repair pathways as these enzymes fulfill both cleavage and immediate resealing of the processed DNA, allowing precise, predictable and efficient genome editing in vivo. We use substrate-linked directed evolution coupled with rational design to program SSRs to target therapeutically relevant human genomic sites. Examples of our work will be presented, including the development and application of the broad-range anti-HIV-1 recombinase, Brec1. Because Brec1 efficiently and specifically eradicates the integrated HIV-1 provirus in humanized PDX models, it represents a promising new agent with curative potential.

Speaker: Prof. Dr. Min Ae Lee Kirsch, UKD, Clinic and Policlinic for Children and Youth Medicine

Title: "Therapeutic genome editing - promise and peril"

Abstract: Gene editing technologies pose significant implications for human health and disease. At the same time this technological innovation fundamentally impacts our role and responsibility as scientists in the societal and ethical debate as well as in policy-making processes. What are the real and perceived potential benefits and problems created by gene editing? How can we manage risks and benefits?

Start date: April 12
02:00 pm 05:00 pm


International Master‘s Courses // Center for Molecular and Cellular Bioengineering (CMCB)

Students of biology, life sciences, medicine, bio-chemistry, physics and similar subjects with an interest in an international Master’s program taught in English

― Introduction of the Master’s courses Molecular Bioengineering, Nanobiophysics, and Regenerative Biology and Medicine
― Lab visit
― Opportunity to talk to the CMCB student council (Fachschaftsrat) and the course coordinators
― PhD/PostDoc Talk & Social Hour

12 April 2019, 2 – 5pm

Technische Universität Dresden
Center for Regenerative Therapies Dresden (CRTD)
Fetscherstr. 105, 01307 Dresden

Please sign-up until 22 March 2019:
Please provide your name, university / course of study, semester.

Find the flyer here: https://crt-dresden.de/fileadmin/Press_Releases/InformationDay_2019.pdf

Dynamics of..
Start date: April 12
04:00 pm 05:00 pm



The liver is an organ with an enormous regenerative capacity and has been studied extensively in the past to understand this extraordinary property. Especially the parenchymal hepatocytes were analyzed in this context. Yet, the specific aspects of human hepatocyte renewal are still unclear as investigation of this process in man is very difficult due to methodological restrictions. Therefore, actual knowledge of the life time of human hepatocytes is limited and the respective source of new cells under different conditions is discussed.

Our aim is to advance these substantial questions of human liver cell renewal utilizing a method which is new to the field - namely radiocarbon dating. We are using this technique to quantify the extent of hepatocyte renewal in human liver tissue. Having analyzed a first set of samples, we are now extending our study with regard to more specific aspects, including the zonation in the liver lobule and analysis of hepatocyte ploidy. Based on our data we are developing a mathematical model for human hepatocyte turnover. These studies will add substantially to the current knowledge and can provide the basis for treatment strategies aiming at pharmacologically manipulating hepatocyte renewal to improve liver function in advanced liver disease.

Page 1 of 1 1

To the top of this page.